NCT01204086

Pharmacogenomics Studies of Antidepressants

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: National Cheng-Kung University Hospital · Academic / Other
• Sex: All
• Age: 16 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to establish the clinical effectiveness of antidepressants by pharmacogenomic approach, and to determine the levels of inflammatory factors between the baseline and the end point of the study in Taiwanese major depressive disorder (MDD) patients.

Conditions

• Major Depressive Disorder
• Antidepressive Agents
• Pharmacogenetics
• Venlafaxine
• Fluoxetine

Interventions

Type	Name	Description
DRUG	Venlafaxine	The initial dose of venlafaxine was 37.5 mg once daily for 4 days titrated to 75 mg once daily, which could be increased by 75 mg in divided doses to a maximal daily dose of 225 mg.
DRUG	Fluoxetine	The initial dose of fluoxetine was 20 mg once daily, which could be increased by 20 mg in divided doses to a maximal daily dose of 80 mg.

Timeline

• Start date: 2007-03-01
• Primary completion: 2010-12-01
• Completion: 2011-02-01
• First posted: 2010-09-17
• Last updated: 2010-09-17

Locations

1 site across 1 country: Taiwan